- Clinical Trials
Our oncology platform technologies have been designed and optimized to administer cancer-fighting genes to large patient populations who currently have limited treatment options. We are developing our lead product candidate to be administered in combination with approved therapies, such as targeted therapies and immunotherapies, for NSCLC. We have conducted a Phase I/II targeted therapy clinical trial evaluating GPX-001 in combination with EGFR inhibitor erlotinib. We have conducted preclinical research evaluating GPX-001 in combination with EGFR inhibitor osimertinib (Astra Zeneca’s Tagrisso®), as well as GPX-001 in combination with checkpoint inhibitor pembrolizumab (Merck’s Keytruda®). Genprex continues to conduct preclinical research to explore how GPX-001 may be administered with targeted therapies and immunotherapies in other solid tumors. Investigators at the University of Pittsburgh are also continuing to conduct preclinical research on our diabetes gene therapy candidate. Our current research and development pipeline is shown below.
Tagrisso® is a registered trademark of AstraZeneca.
Keytruda® is a registered trademark of Merck.